BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the 2022 BIO CEO & Investor Conference.
TransCode’s Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific discoveries that it believes has the potential to significantly advance the treatment of cancer, including the company’s lead therapeutic candidate designed to treat metastatic disease. The Company is planning to file an exploratory Investigational New Drug application (eIND) with the FDA by the second half of this year. If approved, this First-in-Human clinical trial is intended to demonstrate delivery of TransCode’s lead candidate to metastatic lesions in Stage IV breast cancer patients and evaluate biodistribution and pharmacokinetics of the drug.
The presentation will be webcast by the Conference. An archived recording will be made available in the Investors’ section of TransCode Therapeutics’ website.
| Event: | 2022 BIO CEO & INVESTOR CONFERENCE |
| Date: | February 14-17, 2022 |
| Presentation: | Available February 14, 2022 |
| Conference: TransCode Website: | https://www.bio.org/events/bio-ceo-investor-conference/sessions/881958 https://ir.transcodetherapeutics.com |
About TransCode Therapeutics
TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b, a well-documented biomarker of cancer metastasis, which is believed to cause approximately 90% of all cancer deaths totaling over nine million deaths last year alone. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colorectal cancer, glioblastomas and others. Two of the Company’s other drug candidates, TTX-siPDL1 and TTX- siLIN28b, focus on treating tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing other therapeutic candidates and diagnostic products related to its planned therapeutics business.
Forward-looking Statement
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the timing and outcome of expected regulatory filings and clinical trials, including the filing of an eIND for the planned first-in-human study of TTX-MC138, and statements concerning the timing and outcome of this study, including whether this study will demonstrate proof-of-concept, and statements concerning TransCode’s development programs and TTX technology platform generally. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk associated with drug discovery and development; the risk that the results of our planned clinical trials will not be consistent with our pre-clinical studies or expectations; risks associated with the timing and outcome of TransCode s planned regulatory submissions; risks associated with TransCode’s planned clinical trials for its product candidates; risks associated with obtaining, maintaining and protecting intellectual property; risks associated with TransCode’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risks associated with TransCode’s financial condition and its need to obtain additional funding to support its business activities, including TransCode’s ability to continue as a going concern; risks associated with TransCode’s dependence on third parties; and risks associated with the COVID-19 coronavirus. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause
TransCode’s actual results to differ from those contained in or implied by the forward-looking statements, see the section entitled “Risk Factors” in TransCode’s Quarterly Report on Form 10-Q for the period ended September 30, 2021, as well as discussions of potential risks, uncertainties and other important factors in any subsequent TransCode filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release; TransCode undertakes no duty to update this information unless required by law.
For further information: TransCode Therapeutics, Inc.
Alan Freidman, VP Investor Relations Alan.freidman@transcodetherapeutics.com
